Business
Quest Announces that OncoQuest Pharmaceuticals Inc. Doses First Patient in Phase 3 Clinical Trial, FLORA-5, of Company's Lead Investigational Drug, Oregovomab, in Frontline Ovarian Cancer and appoints Dr. Sunil Gupta as Chief Medical Officer
Quest Announces that OncoQuest Pharmaceuticals Inc. Doses First Patient in Phase 3 Clinic...
About this update from Quest Pharmatech Inc.
[{"type":"text","content":"\n \n \n \n Quest Announces that OncoQuest Pharmaceuticals Inc. Doses First Patient in Phase 3 Clinical Trial, FLORA-5, of Company's Lead Investigational Drug, Oregovomab, in Frontline Ovarian Cancer and appoints Dr. Sunil Gupta as Chief Medical Officer\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n EDMONTON, AB, Nov. 9, 2020\n \n \n \n \n \n TSX Venture: QPT\n \n \n \n \n EDMONTON, AB\n \n ,\n \n Nov. 9, 2020\n \n /CNW/ - Quest PharmaTech Inc. (TSXV: QPT) announces that OncoQuest Pharmaceuticals, Inc.,\n \n Seoul, South Korea\n \n (078590.KQ) (\"OQP\") has begun dosing patients in the\n \n USA\n \n for the Phase 3 clinical trial of its immunotherapeutic drug candidate oregovomab. This global pivotal trial is expected to enroll 602 patients from 140 clinical sites in 17 countries.\n \n \n The Phase 3 clinical trial called FLORA-5/GOG-3035, is a double-blind, placebo-controlled, multicenter clinical study to compare the safety and efficacy of oregovomab versus placebo when administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin) for the treatment of newly diagnosed patients with advanced epithelial ovarian, fallopian tube or peritoneal carcinoma, in conjunction with optimal debulking surgical resection. The primary and secondary endpoints, for both the adjuvant and neoadjuvant cohorts of this trial, are progression free survival and overall survival, respectively.\n \n \n The FLORA-5 trial is being conducted in collaboration with the Gynecologic Oncology Group Foundation in the US and IQVIA (a clinical research organization).\n \n Greater China\n \n area clinical trials are conducted in collaboration with OncoVent, a Shenzhen Hepalink Pharmaceuticals Group Company in\n \n China\n \n , which is also the commercialization license holder of oregovomab for\n \n China\n \n . \"OncoVent is glad to enter into a Clinical Trial Collaboration Agreement with OncoQuest Pharmaceuticals and participate in this global Phase 3 clinical trial\" said Dr.\n \n Yuenian Eric S...